CD274 and cancer: Immunotherapy is an emerging cancer therapy with potential great success; however, one type of cancer immunotherapy, immune checkpoint inhibitor (anti-PD-1/PD-L1), has response rates of only 10–30% in the clinical treatment [29–33] because of immunosuppressive TME [10].